UC San Diego, Georgia Tech, and Emory researchers develop a hydrogel to mitigate right ventricle damage in children with hypoplastic left heart syndrome.

A new injectable hydrogel developed by UC San Diego, Georgia Tech, and Emory researchers can mitigate right ventricle damage in children with hypoplastic left heart syndrome, a congenital heart defect. The hydrogel, made from cardiac extracellular matrix, encourages self-cell repopulation and improves heart function, potentially increasing life expectancy and enhancing quality of life. The treatment is set to undergo FDA-approved clinical trials.

March 06, 2024
3 Articles